Walleye Trading’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-1,000
Closed -$70K 4640
2018
Q3
$70K Buy
+1,000
New +$65.4K ﹤0.01% 4399
2017
Q4
Sell
-3,800
Closed -$233 4343
2017
Q3
$233 Buy
3,800
+900
+31% +$51.2K ﹤0.01% 3118
2017
Q2
$153 Buy
2,900
+1,000
+53% +$48.8K ﹤0.01% 3288
2017
Q1
$92 Sell
1,900
-5,000
-72% -$232K ﹤0.01% 3447
2016
Q4
$276K Buy
6,900
+4,100
+146% +$175K ﹤0.01% 2562
2016
Q3
$138K Buy
+2,800
New +$133K ﹤0.01% 3060

Other funds holding BIB

Walleye Trading's BIB Position: Q4 2018 in Review

Walleye Trading sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q4 2018, closing a stake of 393 shares — an estimated $27K sold.

Walleye Trading first reported a position in BIB in Q3 2016 and held it in 6 quarters. The position peaked at $27K in Q3 2018. 27 funds tracked by Wall St. Rank hold BIB as of Q4 2018.

  • Walleye Trading reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q4 2018 after selling out during the quarter.
  • Walleye Trading sold 393 ProShares Ultra NASDAQ Biotechnology shares in Q4 2018, an estimated $27K.
  • Walleye Trading first reported a position in ProShares Ultra NASDAQ Biotechnology in Q3 2016 and held it in 6 quarters.
  • Walleye Trading's ProShares Ultra NASDAQ Biotechnology position peaked at $27K in Q3 2018.
  • 27 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2018.

Based on Walleye Trading's 13F filing for Q4 2018, filed 14 Feb 2019.